Barriers to Male Infertility Care and Strategic Solutions for Advancement: Increasing Access, Health Policy, and Advocacy Efforts

Male factor drives up to 50% of infertility cases, yet insurance and specialist access lag far behind

Journal: Urology | Published: 2026-01-30 | Type: Journal Article, Review | PMID: 41621460 Authors: Shandley LM (InVia Fertility, Hoffman Estates, IL); Kahlenberg Z, Obuekwe O, Khodamoradi K, Muthigi A (Dept. of Urology, Houston Methodist Hospital); Kotha R (University of South Florida - Tampa) Funding/COI: Funding source not listed; authors report no competing financial interests

Summary

This is a narrative review, not a study with new data. The authors lay out why men with infertility often don't get diagnosed or treated - geography, cost, insurance gaps, and a shortage of reproductive urologists - and propose fixes: telemedicine, at-home semen testing, insurance advocacy, and expanding subspecialty training.

Claims

• Up to 50% of couples experiencing infertility have a male factor component
• Male infertility is underrecognized, undertreated, and undercovered by insurance (no effect sizes or prevalence data given for these claims)
• Telemedicine, at-home/direct-to-consumer semen analysis, insurance advocacy, and expanded reproductive urology training are proposed as access solutions

Study Quality

This is a review article, so there's no primary data, control group, or statistical analysis to evaluate. The abstract doesn't specify whether the literature search was systematic (defined databases, search terms, inclusion criteria) or a narrative synthesis of the authors' chosen sources - the latter is far more common for this journal and topic, and nothing in the abstract suggests otherwise.

The core "50%" statistic is a widely cited figure in reproductive urology, but the abstract gives no primary source or confidence interval for it, and no numbers back the "underrecognized, undertreated, undercovered" claims. Solutions like at-home semen testing are proposed without discussion of accuracy relative to lab-based semen analysis, which matters given that home kits have historically underperformed on motility assessment.

Red Flags

• No stated methodology for how the literature was selected (not confirmed systematic)
• No effect sizes, prevalence rates, or citations behind the central access-barrier claims in the abstract
• Funding source not disclosed ("Not listed"), which is itself worth noting for a policy-advocacy piece
• Proposed solutions (direct-to-consumer testing, telemedicine) aren't weighed against their own limitations or evidence base

Strengths

• Addresses a genuinely underdiscussed gap: male infertility gets far less insurance and specialist infrastructure than female infertility despite comparable prevalence
• Multi-institutional author group spanning academic urology and private fertility practice
• No competing financial interests declared
• Proposes concrete, actionable policy directions (insurance advocacy, subspecialty training expansion) rather than vague calls for "awareness"

Verdict

Worth a skim for the framing, not for evidence. It's an opinion/policy review dressed as a paper - useful for understanding what reproductive urologists are lobbying for, but it doesn't bring new data, and the abstract's key statistics arrive uncited. Treat the "50%" figure and the access-barrier claims as background context, not as findings this paper established.